Cited by 3,063Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Open access

Hellmann, Matthew D., Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory A., Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S., Brahmer, Julie, Reck, Martin, O’Byrne, Kenneth J., Geese, William J., Green, George, Chang, Han, Szustakowski, Joseph, Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, Paz-Ares, Luis·2018·New England Journal of Medicine

DOI 10.1056/nejmoa1801946PMC PMC7193684

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 mutations per megabase). METHODS: We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy. Those with a level of tumor programmed death ligand 1 (PD-L1) expression of at least 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy; those with a tumor PD-L1 expression level of less than 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. Tumor mutational burden was determined by the FoundationOne CDx assay. RESULTS: Progression-free survival among patients with a high tumor mutational burden was significantly longer with nivolumab plus ipilimumab than with chemotherapy. The 1-year progression-free survival rate was 42.6% with nivolumab plus ipilimumab versus 13.2% with chemotherapy, and the median progression-free survival was 7.2 months (95% confidence interval [CI], 5.5 to 13.2) versus 5.5 months (95% CI, 4.4 to 5.8) (hazard ratio for disease progression or death, 0.58; 97.5% CI, 0.41 to 0.81; P<0.001). The objective response rate was 45.3% with nivolumab plus ipilimumab and 26.9% with chemotherapy. The benefit of nivolumab plus ipilimumab over chemotherapy was broadly consistent within subgroups, including patients with a PD-L1 expression level of at least 1% and those with a level of less than 1%. The rate of grade 3 or 4 treatment-related adverse events was 31.2% with nivolumab plus ipilimumab and 36.1% with chemotherapy. ical; CheckMate 227 ClinicalTrials.gov number, NCT02477826 .). CONCLUSIONS: Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of PD-L1 expression level. The results validate the benefit of nivolumab plus ipilimumab in NSCLC and the role of tumor mutational burden as a biomarker for patient selection. (Funded by Bristol-Myers Squibb and Ono Pharmaceut

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1801946

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citation
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citation
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citation
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839

Flagged first, then by citations

Show all 22 references

Sorted by citations

Items 101–200 of 1,002

Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
Bodor, J. N., Boumber, Y., & Borghaei, H. (2019) · Cancer · doi:10.1002/cncr.32468 · Cited by 338
Self-citation
Recent advances in non-small cell lung cancer targeted therapy; an update review
Araghi, M., Mannani, R., Maleki, A. H., Hamidi, A., Rostami, S. M., Safa, S. H., Faramarzi, F., Khorasani, S., Alimohammadi, M., Tahmasebi, S., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02990-y · Cited by 374
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers
Offin, M. D., Rizvi, H. A., Tenet, M., Ni, A., Sánchez-Vega, F., Li, B. T., Drilon, A. E. D. C., Kris, M. G., Rudin, C. M., Schultz, N. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1102 · Cited by 336
Self-citation
Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
Song, P., Wu, L. R., Yan, Y. H., Zhang, J. X., Chu, T., Kwong, L. N., Patel, A. A., & Zhang, D. Y. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00837-3 · Cited by 334
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
Sabari, J. K., Leonardi, G. C., Shu, C. A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy334 · Cited by 321
Self-citation
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
Herbst, R. S., Garon, E. B., Kim, D., Cho, B. C., Gervais, R., Perez‐Gracia, J. L., Han, J., Majem, M., Forster, M. D., Monnet, I., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.001 · Cited by 320
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Paz-Ares, L. G., Ramalingam, S. S., Ciuleanu, T., Lee, J.-S., Urban, L., Caro, R. B., Park, K., Sakai, H., Ohe, Y., Nishio, M., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.09.010 · Cited by 331
Self-citation
Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort
Ready, N. E., Ott, P. A., Hellmann, M. D., Zugazagoitia, J., Hann, C. L., de Braud, F., Antonia, S. J., Ascierto, P. A., Moreno, V., Atmaca, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.004 · Cited by 315
Self-citation
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Ruf, B., Heinrich, B., & Greten, T. F. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00572-w · Cited by 318
Biomarker Testing for Patients With Advanced Non–Small Cell Lung Cancer: Real-World Issues and Tough Choices
Pennell, N. A., Arcila, M. E., Gandara, D. R., & West, H. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237863 · Cited by 320
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Fancello, L., Gandini, S., Pelicci, P. G., & Mazzarella, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0647-4 · Cited by 325
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Goodman, A. M., Sokol, E. S., Frampton, G. M., Lippman, S. M., & Kurzrock, R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0149 · Cited by 310
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer
Bott, M. J., Yang, S. C., Park, B. J., Adusumilli, P. S., Rusch, V. W., Isbell, J. M., Downey, R. J., Brahmer, J. R., Battafarano, R. J., Bush, E. L., et al. (2018) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2018.11.124 · Cited by 307
Self-citation
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A. R., & Boland, G. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 330
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J., Pasero, P., & Postel-Vinay, S. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 306
A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients
Cursons, J., Souza-Fonseca-Guimarães, F., Foroutan, M., Anderson, A., Hollande, F., Hediyeh-zadeh, S., Behren, A., Huntington, N. D., & Davis, M. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0500 · Cited by 312
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
Negrao, M. V., Skoulidis, F., Montesion, M., Schulze, K., Bāra, I., Shen, V., Xu, H., Hu, S., Sui, D., Elamin, Y. Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002891 · Cited by 307
Self-citation
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 296
Trial watch: STING agonists in cancer therapy
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777624 · Cited by 289
High-dose vitamin C enhances cancer immunotherapy
Magrì, A., Germano, G., Lorenzato, A., Lamba, S., Chilà, R., Montone, M., Amodio, V., Ceruti, T., Sassi, F., Arena, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8707 · Cited by 285
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Sholl, L. M., Hirsch, F. R., Hwang, D. M., Botling, J., López‐Ríos, F., Bubendorf, L., Mino-Kenudson, M. A., Roden, A. C., Beasley, M. B., Borczuk, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.019 · Cited by 286
Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition
Li, Y., Zhao, R., Cheng, K., Zhang, K., Wang, Y., Zhang, Y., Li, Y., Liu, G., Xu, J., Xu, J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c03776 · Cited by 285
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
Kim, C. G., Kim, K. H., Pyo, K., Xin, C.-F., Hong, M. H., Ahn, B., Kim, Y., Choi, S. J., Yoon, H. I., Lee, J. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz123 · Cited by 286
Self-citation
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
Owonikoko, T. K., Park, K., Govindan, R., Ready, N., Reck, M., Peters, S., Dakhil, S. R., Navarro, A., Rodríguez‐Cid, J. R., Schenker, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02212 · Cited by 273
Self-citation
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Ma, K., Talbot, T., Monnet, I., Hiret, S., Baas, P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.01.074 · Cited by 281
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
Fabrizio, D. A., George, T. J., Dunne, R. F., Frampton, G. M., Sun, J. X., Gowen, K. A., Kennedy, M., Greenbowe, J. R., Schrock, A. B., Hezel, A. F., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.05.06 · Cited by 266
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer
Yu, Y., Zeng, D., Ou, Q., Liu, S., Li, A., Chen, Y., Lin, D., Gao, Q., Zhou, H., Liao, W., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.6879 · Cited by 264
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
Powles, T. B., Yuen, K. C. Y., Gillessen, S., Kadel, E. E., Rathkopf, D. E., Matsubara, N., Drake, C. G., Fizazi, K. S., Piulats, J. M., Wysocki, P. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01600-6 · Cited by 268
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11030320 · Cited by 273
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 257
Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients
Hwang, I., Kim, J. W., Ylaya, K., Chung, E. J., Kitano, H., Perry, C. D., Hanaoka, J., Fukuoka, J., Chung, J., & Hewitt, S. M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02618-z · Cited by 258
A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma
Wu, J., Li, L., Zhang, H., Zhao, Y., Zhang, H., Wu, S., & Xu, B. (2021) · Oncogene · doi:10.1038/s41388-021-01853-y · Cited by 255
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Brahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., Dubinett, S. M., Ferris, A. A., Gandhi, L., Garon, E. B., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0382-2 · Cited by 253
Self-citation
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Boyer, M. J., Şendur, M. A. N., Rodríguez‐Abreu, D., Park, K., Lee, D. H., Çiçin, İ., Yumuk, P. F., Orlandi, F., Leal, T. A. B., Molinier, O., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03579 · Cited by 253
Self-citation
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Montesion, M., Murugesan, K., Jin, D. X., Sharaf, R., Sánchez, N., Guria, A., Minker, M., Li, G., Fisher, V. A., Sokol, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0672 · Cited by 253
Trial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Progress and challenges of immunotherapy in triple-negative breast cancer
Zhu, Y., Zhu, X., Tang, C., Guan, X., & Zhang, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188593 · Cited by 242
The Extrinsic and Intrinsic Roles of PD‐L1 and Its Receptor PD‐1: Implications for Immunotherapy Treatment
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
Sharma, P., Siefker-Radtke, A. O., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J. A., Brossart, P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00538 · Cited by 244
Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions
Stenzinger, A., Allen, J. D., Maas, J., Stewart, M. D., Merino, D. M., Wempe, M. M., & Dietel, M. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22733 · Cited by 245
Genomic and evolutionary classification of lung cancer in never smokers
Zhang, T., Joubert, P., Ansari‐Pour, N., Wei, Z., Hoang, P. H., Lokanga, R. A., Moye, A. L., Rosenbaum, J., González-Pérez, A., Martínez-Jiménez, F., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00920-0 · Cited by 243
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
Fumet, J.-D., Truntzer, C., Yarchoan, M. M., & Ghiringhelli, F. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.038 · Cited by 242
Comprehensive T cell repertoire characterization of non-small cell lung cancer
Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14273-0 · Cited by 220
Self-citation
Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
Hendriks, L. E. L., Henon, C., Auclin, É., Mezquita, L., Ferrara, R., Audigier-Valette, C., Mazières, J., Lefebvre, C., Rabeau, A., Moulec, S. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.009 · Cited by 240
Self-citation
STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
Papillon‐Cavanagh, S., Doshi, P. D., Dobrin, R., Szustakowski, J. D., & Walsh, A. M. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000706 · Cited by 240
Self-citation
Cell membrane coated-nanoparticles for cancer immunotherapy
Zeng, Y., Li, S., Zhang, S., Wang, L., Yuan, H., & Hu, F. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.023 · Cited by 238
Methods of measurement for tumor mutational burden in tumor tissue
Meléndez, B., Campenhout, C. V., Rorive, S., Remmelink, M., Salmon, I. J., & D’Haene, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.02 · Cited by 238
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Llovet, J. M., Montal, R., & Villanueva, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.028 · Cited by 234
The cutting-edge progress of immune-checkpoint blockade in lung cancer
Zhou, F., Qiao, M., & Zhou, C. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00577-5 · Cited by 239
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Krämer, A., Bochtler, T., Pauli, C., Baciarello, G., Delorme, S., Hemminki, K., Mileshkin, L., Moch, H., Oien, K. A., Olivier, T., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.11.013 · Cited by 245
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Mino-Kenudson, M. A., Schalper, K. A., Cooper, W. A., Đačić, S., Hirsch, F. R., Jain, D., López‐Ríos, F., Tsao, M., Yatabe, Y., Beasley, M. B., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.109 · Cited by 240
Rational design of anti-GITR-based combination immunotherapy
Zappasodi, R., Sirard, C. A., Li, Y., Budhu, S., Abu-Akeel, M., Liu, C., Yang, X., Zhong, H., Newman, W., Qi, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0420-8 · Cited by 233
Self-citation
Inferring gene expression from cell-free DNA fragmentation profiles
Esfahani, M. S., Hamilton, E. G., Mehrmohamadi, M., Nabet, B. Y., Alig, S., King, D. A., Steen, C. B., Macaulay, C. W., Schultz, A., Nesselbush, M. C., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01222-4 · Cited by 234
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
Duruisseaux, M., Martínez‐Cardús, A., Calleja-Cervantes, M. E., Morán, S., de Moura, M. C., Dávalos, V., Piñeyro, D., Sánchez‐Céspedes, M., Girard, N., Brevet, M., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30284-4 · Cited by 231
Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
Osa, A., Uenami, T., Koyama, S., Fujimoto, K., Okuzaki, D., Takimoto, T., Hirata, H., Yano, Y., Yokota, S., Kinehara, Y., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.59125 · Cited by 227
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Dafni, U. G., Tsourti, Z., Vervita, K., & Peters, S. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.029 · Cited by 226
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Planes-Laine, G., Rochigneux, P., Bertucci, F., Chrétien, A.-S., Viens, P., Sabatier, R., & Gonçalvès, A. (2019) · Cancers · doi:10.3390/cancers11071033 · Cited by 227
Advancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · 癌症：英文版 · doi:10.1002/cac2.12178 · Cited by 221
Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
Hwang, S., Kwon, A.-Y., Jeong, J.-Y., Kim, S., Kang, H., Park, J., Kim, J.-H., Han, O. J., Lim, S. M., & An, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-019-57218-9 · Cited by 215
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Reck, M., Schenker, M., Lee, K. H., Provencio, M., Nishio, M., Leśniewski-Kmak, K., Sangha, R. S., Ahmed, S. I., Raimbourg, J., Feeney, K., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.05.008 · Cited by 220
Self-citation
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
Botticelli, A., Vernocchi, P., Marini, F., Quagliariello, A., Cerbelli, B., Reddel, S., Del Chierico, F., Di Pietro, F., Giusti, R., Tomassini, A., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02231-0 · Cited by 209
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer
Cook, M. R., & Kim, C. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6737 · Cited by 217
Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians
Allgäuer, M., Budczies, J., Christopoulos, P., Endris, V., Lier, A., Rempel, E., Volckmar, A., Kirchner, M., von Winterfeld, M., Leichsenring, J., et al. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.14 · Cited by 212
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Cheng, W., Kang, K., Zhao, A., & Wu, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01581-2 · Cited by 229
Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
Hofland, J., Kaltsas, G., & de Herder, W. W. (2019) · Endocrine Reviews · doi:10.1210/endrev/bnz004 · Cited by 211
Cancer immunotherapy: it’s time to better predict patients’ response
Pilard, C., Ancion, M., Delvenne, P., Jérusalem, G., Hubert, P., & Herfs, M. F. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01413-x · Cited by 224
Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Fang, W., Ma, Y., Yin, J. C., Hong, S., Zhou, H., Wang, A., Wang, F., Bao, H., Wu, X., Yang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0585 · Cited by 209
Precision Management of Advanced Non–Small Cell Lung Cancer
Yang, C., Yang, J. C., & Yang, P. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 212
Immune-based therapies for hepatocellular carcinoma
Pinato, D. J., Guerra, N., Fessas, P., Murphy, R., Mineo, T., Mauri, F. A., Mukherjee, S. K., Thursz, M. R., Wong, C. N., Sharma, R., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1249-9 · Cited by 202
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
D’Angelo, S. P., Bhatia, S., Brohl, A. S., Hamid, O., Mehnert, J. M., Terheyden, P. A. M., Shih, K. C., Brownell, I., Lebbé, C., Lewis, K. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000674 · Cited by 207
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman, P. M., Heeke, S., Alix‐Panabières, C., & Pantel, K. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz196 · Cited by 205
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
Anagnostou, V., Niknafs, N., Marrone, K. A., Bruhm, D. C., White, J. R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M. R., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0008-8 · Cited by 204
Self-citation
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
Sui, H., Ma, N., Wang, Y., Li, H., Liu, X., Su, Y., & Yang, J. (2018) · Journal of Immunology Research · doi:10.1155/2018/6984948 · Cited by 207
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R. A., Lesh, R. W., Ali, U., Kubiak, M. J., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 202
Self-citation
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 209
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Feng, Q. F., & He, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00858 · Cited by 202
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
Johnson, D. H., Zobniw, C. M., Trinh, V. A., Ma, J., Bassett, R. L., Abdel‐Wahab, N., Anderson, J. E., Davis, J. E., Joseph, J., Uemura, M. I., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0412-0 · Cited by 196
Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Prelaj, A., Tay, R. Y., Ferrara, R., Chaput, N., Besse, B., & Califano, R. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.002 · Cited by 197
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
Chin, R.-I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., & Chaudhuri, A. A. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00390-5 · Cited by 191
Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
He, B., Dong, D., She, Y., Zhou, C., Fang, M., Zhu, Y., Zhang, H., Huang, Z., Jiang, T., Tian, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000550 · Cited by 194
Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer
Atchley, W. T., Álvarez, C., Saxena, S., Schwartz, T. A., Ishizawar, R. C., Patel, K. P., & Rivera, M. P. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.02.032 · Cited by 193
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
Reck, M., Ciuleanu, T., Cobo, M., Schenker, M., Żurawski, B. A., Menezes, J. J. D., Richardet, E., Bennouna, J., Felip, E., Juan, Ó., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100273 · Cited by 192
Self-citation
Trial watch: IDO inhibitors in cancer therapy
Naour, J. L., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777625 · Cited by 195
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
Pesce, S., Greppi, M., Grossi, F., Zotto, G. D., Moretta, L., Sivori, S., Genova, C., & Marcenaro, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01242 · Cited by 188
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C. S., Tan, D. S. W., Lee, D., Misch, D., Garralda, E., Kim, D.-W., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.002 · Cited by 186
Self-citation
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
Suresh, K., Psoter, K. J., Voong, K. R., Shankar, B., Forde, P. M., Ettinger, D. S., Marrone, K. A., Kelly, R. J., Hann, C. L., Levy, B., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.016 · Cited by 186
Self-citation
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature · doi:10.1038/s41586-024-07943-7 · Cited by 194
Self-citation
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 188
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Barroso‐Sousa, R., Keenan, T. E., Pernas, S., Exman, P., Jain, E., Garrido-Castro, A. C., Hughes, M. E., Bychkovsky, B., Umeton, R., Files, J. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3507 · Cited by 187
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
Onoi, K., Chihara, Y., Uchino, J., Shimamoto, T., Morimoto, Y., Iwasaku, M., Kaneko, Y., Yamada, T., & Takayama, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051362 · Cited by 183
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Alva, A. S., Mangat, P. K., Garrett-Mayer, E. S., Halabi, S., Hansra, D. M., Calfa, C. J., Khalil, M. F., Ahn, E. R., Cannon, T. L., Crilley, P. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02923 · Cited by 188
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
Haragan, A., Field, J. K., Davies, M. P. A., Escriu, C., Gruver, A. M., & Gosney, J. R. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.005 · Cited by 183
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Corte, C. M. D., Sen, T., Gay, C. M., Ramkumar, K., Diao, L., Cardnell, R. J., Rodriguez, B. L., Stewart, C. A., Papadimitrakopoulou, V. A., Gibson, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.009 · Cited by 181
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
Vega, D. M., Yee, L. M., McShane, L. M., Williams, P. M., Chen, L., Vilimas, T., Fabrizio, D. A., Funari, V. A., Newberg, J. Y., Bruce, L. K., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.016 · Cited by 192
Self-citation
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation
Chen, X., Gao, A., Zhang, F., Yang, Z., Wang, S., Fang, Y., Li, J., Wang, J., Shi, W., Wang, L., et al. (2021) · Theranostics · doi:10.7150/thno.52435 · Cited by 184
FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy
Chen, X., Song, X., Li, K., & Zhang, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00292 · Cited by 179
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 176
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
Assoun, S., Théou–Anton, N., Nguenang, M., Cazes, A., Danel, C. J., Abbar, B., Pluvy, J., Gounant, V., Khalil, A., Namour, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.005 · Cited by 171

Authors: Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., Borghaei, H., Ramalingam, S. S., Brahmer, J., Reck, M., O’Byrne, K. J., Geese, W. J., Green, G., Chang, H., Szustakowski, J., Bhagavatheeswaran, P., Healey, D., Fu, Y., Nathan, F., & Paz-Ares, L.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
From Memorial Sloan Kettering Cancer Center Hospital, New York (M.D.H.); Prof. Dr. Ion Chiricuta Institute of Oncology and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Centrum Onkologii–Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland (A.P.); Seoul National University Bundang Hospital, Seoul, South Korea (J.S.L.); Ohio State University, Columbus (G.A.O.); Hôpital Sainte Musse, Toulon, France (C.A.-V.); Ospedale Santa Maria della Misericordia, Perugia,...
Fox Chase Cancer Center (US)
ORCID: Hellmann, Matthew D.
Ciuleanu, Tudor-Eliade
Lee, Jong Seok
Otterson, Gregory A.
Audigier-Valette, Clarisse
Linardou, Helena
Burgers, Sjaak
Salman, Pamela
Borghaei, Hossein
Ramalingam, Suresh S.
Brahmer, Julie
Reck, Martin
Geese, William J.
Green, George
Szustakowski, Joseph
Fu, Yali
Paz-Ares, Luis
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2018-05-31
Volume: 378
Issue: 22
Pages: 2093-2104
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1801946
PMC: PMC7193684
OpenAlex: W2797675588
Cited by: 3,063
References: 22
Citations by year: 2026: 100 · 2025: 184 · 2024: 222 · 2023: 289 · 2022: 419 · 2021: 499 · 2020: 559 · 2019: 542 · 2018: 247
FWCI: 174.31
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Bristol-Myers Squibb, Inc.
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: nivolumab, ipilimumab, non-small cell lung cancer, tumor mutational burden, PD-L1 expression, immune checkpoint inhibitors, progression-free survival, chemotherapy comparison, stage IV lung cancer, treatment-related adverse events, treatment response biomarkers, objective response rate, immunotherapy biomarkers, safety and tolerability
MeSH terms: Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Biomarkers, Tumor, Disease-Free Survival, Kaplan-Meier Estimate, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks